ReShape Lifesciences Inc Cash Flow Conversion Efficiency
ReShape Lifesciences Inc cash flow conversion efficiency. Based on the latest financial reports, ReShape Lifesciences Inc (RSLS) has a cash flow conversion efficiency ratio of -0.771x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.49 Million) by net assets ($5.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ReShape Lifesciences Inc (2005–2024)
Cash flow conversion efficiency of ReShape Lifesciences Inc from 2005 to 2024. This chart illustrates how ReShape Lifesciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RSLS stock price and chart for real-time trading data and today's change.
ReShape Lifesciences Inc Cash Flow Conversion Ratio Explained
ReShape Lifesciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ReShape Lifesciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ReShape Lifesciences Inc ranked by their cash flow conversion efficiency. Also see market value of ReShape Lifesciences Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eastern International Ltd.
NASDAQ:ELOG
|
-0.163x |
|
Polygiene AB
ST:POLYG
|
0.000x |
|
Fourth-Link Inc.
KQ:056730
|
0.045x |
|
Micronet Ltd
TA:MCRNT
|
-0.126x |
|
Viking Kagit ve Seluloz AS
IS:VKING
|
0.725x |
|
M Cash Integrasi Tbk PT
JK:MCAS
|
-0.044x |
|
Blueberry NFT CO.LTD
KQ:044480
|
0.003x |
|
Hengli Industrial Development Group Co Ltd
SHE:000622
|
-0.027x |
Annual Cash Flow Conversion Efficiency for ReShape Lifesciences Inc (2005–2024)
The table below shows the annual cash flow conversion efficiency of ReShape Lifesciences Inc from 2005 to 2024. Review RSLS financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-253.00K | $-4.43 Million | 17.498x | +787.44% |
| 2023-12-31 | $6.66 Million | $-16.96 Million | -2.545x | +57.45% |
| 2022-12-31 | $3.66 Million | $-21.90 Million | -5.983x | -1692.69% |
| 2021-12-31 | $46.07 Million | $-15.38 Million | -0.334x | +43.45% |
| 2020-12-31 | $14.49 Million | $-8.55 Million | -0.590x | -0.18% |
| 2019-12-31 | $24.11 Million | $-14.20 Million | -0.589x | +32.15% |
| 2018-12-31 | $31.66 Million | $-27.49 Million | -0.868x | -169.66% |
| 2017-12-31 | $76.37 Million | $-24.59 Million | -0.322x | +95.42% |
| 2016-12-31 | $2.94 Million | $-20.66 Million | -7.028x | -14.19% |
| 2015-12-31 | $3.67 Million | $-22.61 Million | -6.155x | -111.59% |
| 2014-12-31 | $6.66 Million | $-19.38 Million | -2.909x | -131.72% |
| 2013-12-31 | $14.68 Million | $-18.43 Million | -1.255x | +33.69% |
| 2012-12-31 | $11.88 Million | $-22.48 Million | -1.893x | -90.30% |
| 2011-12-31 | $20.04 Million | $-19.94 Million | -0.995x | -116.26% |
| 2010-12-31 | $29.71 Million | $-13.66 Million | -0.460x | +89.59% |
| 2009-12-31 | $5.58 Million | $-24.66 Million | -4.418x | -49.66% |
| 2008-12-31 | $11.41 Million | $-33.67 Million | -2.952x | -472.02% |
| 2007-12-31 | $45.28 Million | $-23.37 Million | -0.516x | +9.13% |
| 2006-12-31 | $28.57 Million | $-16.23 Million | -0.568x | +89.09% |
| 2005-12-31 | $1.97 Million | $-10.28 Million | -5.205x | -- |
About ReShape Lifesciences Inc
As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling… Read more